Loading
Oncotelic
  • Home
  • PDAOAI
  • Pipeline
  • OT-101
  • About Us
  • Investors
    • Corporate Videos
    • Investor Overview
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Events & Presentations
    • Investor Contacts
    • Email Alerts
    • Corporate Governance
  • Contact
  • Search
  • Menu Menu

Running & Spinning

Gymnastics

Pumping Iron

Crossfit

Aerobics

Page 1 of 212

Pages

  • About Us
  • ARTIHealth
  • Contact
  • Corporate Governance
  • Corporate Videos
  • COVID-19
  • EdgePoint
  • Email Alerts
  • Events & Presentations
  • Home
  • Investor Contacts
  • Investor Overview
  • OT-101
  • OXi4503
  • Partnerships
  • PDAOAI
  • Pipeline
  • Press Releases
  • Publication
  • Sample Page
  • SEC Filings
  • Stock Quote

Categories

  • No categories

Archive

    About Oncotelic

    Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).

    IMPORTANT LINKS

    PDAOAI

    Pipeline

    Investors

    Management Team

    Contact Us

    Our Office

    Oncotelic Corporate Headquarters
    29397 Agoura Road, Suite 107
    Agoura Hills, CA 91301

    (650) 635 7000 (main)
    (650) 635 7001 (fax)

    ir@oncotelic.com

    Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
      Scroll to top